Cargando…

Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective

Neuroendocrine tumors (NETs) are classified based on morphology and are graded based on their proliferation rate as either well-differentiated low-grade (G1) to intermediate (G2–G3) or poorly differentiated high-grade neuroendocrine carcinomas (NEC G3). Recently, in gastroenteropancreatic (GEP) NETs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prisciandaro, Michele, Antista, Maria, Raimondi, Alessandra, Corti, Francesca, Morano, Federica, Centonze, Giovanni, Sabella, Giovanna, Mangogna, Alessandro, Randon, Giovanni, Pagani, Filippo, Prinzi, Natalie, Niger, Monica, Corallo, Salvatore, Castiglioni di Caronno, Erica, Massafra, Marco, Bartolomeo, Maria Di, de Braud, Filippo, Milione, Massimo, Pusceddu, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856722/ https://www.ncbi.nlm.nih.gov/pubmed/35186729 http://dx.doi.org/10.3389/fonc.2022.780716

Ejemplares similares

Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan
por: Pietrantonio, Filippo, et al.
Publicado: (2020)

The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence
por: Pusceddu, Sara, et al.
Publicado: (2020)

Prognostic impact of ATM mutations in patients with metastatic colorectal cancer
por: Randon, Giovanni, et al.
Publicado: (2019)

Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors
por: Pusceddu, Sara, et al.
Publicado: (2020)

One size does not fit all for pancreatic cancers: A review on rare histologies and therapeutic approaches
por: Niger, Monica, et al.
Publicado: (2020)

The Landscape of Actionable Gene Fusions in Colorectal Cancer
por: Pagani, Filippo, et al.
Publicado: (2019)

Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study
por: Pusceddu, Sara, et al.
Publicado: (2021)

Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial
por: Corti, Francesca, et al.
Publicado: (2023)

Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O(6)-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial
por: Morano, Federica, et al.
Publicado: (2022)

Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Pusceddu, Sara, et al.
Publicado: (2019)

Microenvironment and tumor inflammatory features improve prognostic prediction in gastro‐entero‐pancreatic neuroendocrine neoplasms
por: Milione, Massimo, et al.
Publicado: (2019)

Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms
por: Centonze, Giovanni, et al.
Publicado: (2021)

Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined Groups
por: Centonze, Giovanni, et al.
Publicado: (2020)

Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma
por: Torchio, Martina, et al.
Publicado: (2021)

Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study
por: Fucà, Giovanni, et al.
Publicado: (2022)

MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers
por: Niger, Monica, et al.
Publicado: (2022)

COVID-19 Pandemic: Huge Stress Test for Health System Could Be a Great Opportunity to Update the Workflow in a Modern Surgical Pathology
por: Belfiore, Antonino, et al.
Publicado: (2021)

Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT
por: Scalorbi, Federica, et al.
Publicado: (2021)

Author Correction: Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT
por: Scalorbi, Federica, et al.
Publicado: (2023)

Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
por: Fucà, Giovanni, et al.
Publicado: (2021)

The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice
por: Raimondi, Alessandra, et al.
Publicado: (2019)

Succinate Dehydrogenase B Subunit Immunohistochemical Expression Predicts Aggressiveness in Well Differentiated Neuroendocrine Tumors of the Ileum
por: Milione, Massimo, et al.
Publicado: (2012)

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy
por: Morano, Federica, et al.
Publicado: (2019)

Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors
por: Vernieri, Claudio, et al.
Publicado: (2019)

Multidisciplinary Approach to the Diagnosis of Occult Primary Neuroendocrine Neoplasm: A Clinical Challenge
por: Rossi, Roberta Elisa, et al.
Publicado: (2023)

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer
por: Oddo, Daniele, et al.
Publicado: (2017)

Lung carcinoid tumours: histology and Ki‐67, the eternal rivalry
por: Centonze, Giovanni, et al.
Publicado: (2022)

Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up
por: Vernieri, Claudio, et al.
Publicado: (2016)

The landscape of d16HER2 splice variant expression across HER2-positive cancers
por: Volpi, Chiara Costanza, et al.
Publicado: (2019)

Author Correction: The landscape of d16HER2 splice variant expression across HER2-positive cancers
por: Volpi, Chiara Costanza, et al.
Publicado: (2020)

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial
por: Di Bartolomeo, Maria, et al.
Publicado: (2019)

Impact of Microscopically Positive (≤1 mm) Distal Margins on Disease Recurrence in Rectal Cancer Treated by Neoadjuvant Chemoradiotherapy
por: Sorrentino, Luca, et al.
Publicado: (2023)

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study
por: Pietrantonio, Filippo, et al.
Publicado: (2016)

Gain of ALK Gene Copy Number May Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-Type Status
por: Pietrantonio, Filippo, et al.
Publicado: (2014)

Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal Cancer
por: Randon, Giovanni, et al.
Publicado: (2023)

Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti–EGFR-Based Therapy
por: Randon, Giovanni, et al.
Publicado: (2022)

Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic Implications
por: Simbolo, Michele, et al.
Publicado: (2022)

HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
por: Pietrantonio, Filippo, et al.
Publicado: (2023)

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
por: Di Bartolomeo, Maria, et al.
Publicado: (2015)

Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase
por: Falvella, Felicia Stefania, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pv2f0pdkbssikn9b80kdt394ug